Tarextumab (OMP-59R5), a monoclonal antibody (mAb) against Notch2 and Notch3, has shown promising antitumor activity in several in vitro and in vivo models of SCLC, breast, ovarian, and pancreatic cancer that correlated with downregulation of Notch target genes [205]. Here, NOTCH2 is linked to pancreatic neoplasm.